The pathogenesis underlying the selective degeneration of dopaminergic neurons in Parkinson's disease (PD) 1 is not fully defined, but multiple lines of evidence implicate mitochondrial dysfunction. Thus, defects in complex I of the mitochondrial respiratory chain in the substantia nigra and evidence of oxidative stress have been noted in the brains of PD patients (1, 2) . PD is also associated with exposure to pesticides (3, 4) , many of which are either oxidants or mitochondrial toxins. Rapid onset of Parkinsonism in young adults following injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (5) occurs through its active metabolite, 1-methyl-4-phenylpyridinium, an inhibitor of mitochondrial complex I (6), potentially by depleting energy stores and inducing oxidative stress (7, 8) .
Complex I is specifically and irreversibly inhibited by the neurotoxin rotenone, a hydrophobic pesticide epidemiologically linked to PD. Continuous, systemic, in vivo infusion of 2-3 mg/kg/day rotenone in rats over weeks produces relatively selective nigrostriatal dopaminergic neurodegeneration, with formation of ubiquitin-and ␣-synuclein-positive inclusions (9, 10) . This low dose paradigm results in about 75% inhibition of complex I activity, and corresponds to a brain concentration of 20 -30 nM (9, 10). However, although these studies establish the principle that complex I dysfunction leads to degeneration in dopaminergic neurons, consistent levels of functional deficits related to complex I dysfunction have been difficult to reproduce (11) . Accordingly, this in vivo model has not lent itself easily to the study of the mechanism of rotenone toxicity (12) . Similarly, the use of primary cultures of dopaminergic neurons to study mechanisms of rotenone-induced neurodegeneration has been limited: short term, nanomolar rotenone administration in primary cultures of dopaminergic neurons does not produce selective dopaminergic damage (13) . In addition, primary cultures contain a mixture of dopaminergic and nondopaminergic neurons and therefore do not lend themselves to molecular and biochemical analyses. The use of existing cell lines to study the effects of chronic rotenone exposure (14) also has shortcomings. Most cell lines do not exhibit robust dopaminergic phenotypes. In addition, the high rate of proliferation that characterize these cell lines confound the assessment of cellular susceptibility to rotenone, because proliferating cells may replace those that have succumbed to rotenone, and chronic exposure may lead to the selection of cells that become resistant to rotenone toxicity.
To study the cellular mechanisms of rotenone-induced dopaminergic neuronal degeneration, we therefore developed a novel cellular model derived from immortalized midbrain MN9D cells (15) , a dopaminergic neuronal cell line that has been extensively characterized as a model of dopaminergic neurons (16 -19) . Using sodium butyrate (NaBu) (20) to differentiate MN9D cells and cells from a related, immortalized, non-dopaminergic midbrain neuronal cell line (MN9X cells), we have produced dopaminergic and non-dopaminergic cell cultures that can be maintained in vitro for weeks without pro-liferation. Using these cells, we compared cell degeneration induced by chronic, nanomolar rotenone treatment in dopaminergic and non-dopaminergic cells. Because chronic rotenone exposure can induce oxidative stress and mitochondrial dysfunction, we have used this unique model to examine the roles of oxidative stress and bioenergetic disruption in the selective susceptibility of dopaminergic cells to rotenone neurodegeneration, processes that occur in the setting of chronic low-grade complex I inhibition. We find that this chronic lowgrade complex I inhibition leads to cell degeneration by distinct mechanisms in dopaminergic and non-dopaminergic cells.
EXPERIMENTAL PROCEDURES
Production of Undifferentiated MN9 Cells-MN9 cells were generated by somatic fusion of dissociated neurons from the ventral midbrain of E14 C57BL/6J mice with the hypoxanthine-guanine phosphoribosyltransferase-deficient N18G2 neuroblastoma cell line after exposure to 50% polyethylene glycol and selection against HRPT-deficient cells by Choi et al. (15) at the University of Chicago and provided to us. Clones expressing dopamine were designated as MN9D and those with no dopamine were designated as MN9X. These cell lines have been extensively characterized previously (17, 18, 21) .
Differentiation of MN9 Cells-MN9 cells were grown in Dulbecco's modified Eagle's medium (Invitrogen), with 10% fetal bovine serum (Intergen, Purchase, NY). We differentiated MN9 cells with 1 mM NaBu for 5-6 days. NaBu induces cell cycle arrest and morphological neural differentiation by inhibiting histone deacetylase (20) . Morphological changes were observed within 2 days after the addition of NaBu by phase-contrast microscopy. Fresh media containing experimental compounds were fed every 2-3 days. High glucose (25 mM) media were used except as noted.
Assessment of Cell Viability-For survival studies, 10,000 cells were plated in each well of a 96-well plate to achieve about 50% confluence. Cell survival was measured using Cell Counting Kit-8 (Dojindo Molecular Technologies, Inc., Gaithersburg, MD), which contains a tetrazolium salt (WST-8) that produces a water-soluble formazan dye by NADH dehydrogenases in living cells. To measure cell viability, 10 l of WST-8 assay solution was added to 100 l of phenol red-free medium per well and incubated for 4 h. The optical density (OD) of the solution was read by a microplate reader, using a test wavelength at 450 nm and a reference wavelength at 650 nm. Cell Counting Kit-8 OD was directly proportional to the number of viable cells (n ϭ 28, r ϭ 1.000, p Ͻ 0.001). This assay was also validated with cell counts performed with trypan blue staining of cells after rotenone treatment for 7 days (n ϭ 53, r ϭ 0.878, p Ͻ 0.001).
Measurement of Dopamine and Tetrahydrobiopterin Levels-For dopamine measurement, cells were pelleted and homogenized by sonication in 0.1 M perchloric acid containing 0.1 mM EDTA. The conditioned media were also treated with 0.1 M perchloric acid containing 0.1 mM EDTA. Samples were centrifuged (10,000 ϫ g, 4°C, 10 min) and supernatants were analyzed by high performance liquid chromatography with electrochemical detection (22) . Our detection limit was around 0.3 ϫ 10 Ϫ5 pmol/cell of dopamine. For tetrahydrobiopterin measurement, cells were homogenized in 0.1 M perchloric acid containing 1 mg/ml dithioerythritol and 0.1 mg/ml diethylenetriaminepentaacetic acid (as antioxidants), protein pellets were removed by centrifugation and portions of the supernatants injected onto a C18 reversed phase column for electrochemical detection following high performance liquid chromatography separation (23) . Tetrahydrobiopterin was eluted isocratically and quantitated against external standards.
Immunohistochemistry-Approximately 200,000 differentiated cells were plated on each 12-mm glass coverslip in 24-well plates. Cells were washed with 0.1 M phosphate-buffered saline (PBS) and fixed in 4% paraformaldehyde, 0.1 M phosphate buffer, pH 7.4, for 30 min. Cells were permeabilized with 0.1 M PBS containing 1% bovine serum albumin (Sigma) and 0.2% Triton X-100 for 1 h, then incubated at room temperature overnight in primary antibody, followed by a 1-h incubation with fluorophore-conjugated secondary antibody (1:200) (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). Antibodies against tyrosine hydroxylase antiserum were obtained from Pel-Freeze (Rogers, AR) and used at 1:1,000 dilution. Anti-neurofilament and anti-glial fibrillary acidic protein antibodies were obtained from Sternberger Monoclonals (Baltimore, MD). Anti-glutamic acid decarboxylase antibody was from Stressgen (San Diego, CA). Coverslips were washed and then mounted with Promega Antifade Kit. Stained cells were viewed with epifluorescence illumination, fluorophore-appropriate excitation and emission filters and a ϫ40, 1.4 NA objective. Images were obtained with a cooled CCD camera and Metamorph Imaging software (Universal Imaging Corp.).
ATP Measurements-The intracellular ATP content of differentiated cells were measured by luciferin/luciferase bioluminescence, using a Monolight 3010C Lumenometer. For ATP measurements, cells were grown in 100-mm culture plates, and harvested after 3 days of feeding with control medium or medium supplemented with rotenone. Scraped cells were washed once with 10 mM PBS, pH 7.4, and resuspended in 300 l of cell lysis buffer (0.5 M potassium phosphate, pH 7.8, 2 mM EDTA, 1 mM DL-dithiothreitol, and 1% Triton X-100). Resuspended cells were sonicated and centrifuged at 13,000 ϫ g for 10 min. The supernatant was immediately frozen and stored at Ϫ80°C until analysis. A reaction mixture containing 50 l of reaction buffer (6 mM MgCl 2 and 0.1 M HEPES, pH 7.8), 50 l of sample or standard (10 Ϫ4 , 10 Ϫ5 , 10 Ϫ6 , and 10 Ϫ7 M), and 15 l of firelight LB (Analytical Luminescence Laboratory, Sparks, MD) was added to glass cuvettes immediately before measuring ATP levels.
Mitochondrial Respiration-Oxygen consumption rates for MN9D and MN9X cells were determined by mounting coverslips containing adherent cells in a stainless steel apparatus (Penn Century, Philadelphia, PA). A spacer ring separated the two coverslips, forming a flowthrough chamber that was flushed with a buffered salt solution containing Pd-meso-tetra (4-carboxyphenyl)porphine probe in 0.5% albumin. When filled with this solution, the dissolved oxygen tension decreased at a rate proportional to the respiratory rate of the cells. The PO 2 in the solution was measured every 3 s using a phosphorescence quenching method (24) . The slope obtained from least-squares linear regressions of PO 2 against time was used as a relative indicator of cellular respiration.
Measurement of Mitochondrial Membrane Potential (⌬⌿ m )-Tetramethylrhodamine methylester (TMRM) (Molecular Probes, Eugene, OR), a fluorescent, cationic membrane potential indicator, was used to assess changes in ⌬⌿ m . Cells were incubated for 1 h in culture medium containing 100 nM TMRM. In preliminary experiments, we ascertained that, at this concentration, intramitochondrial TMRM was not quenched at baseline mitochondrial potentials. Cells were illuminated by epifluorescence, using light from a 75 watt xenon source, the intensity of which was decreased to 0.0003% by neutral density filters. This low illumination level enabled time-lapse studies to be performed for up to 1 h at 35°C without light-induced dissipation of ⌬⌿ m . Cells were observed with an inverted microscope (Nikon, Japan) and imaged with a cooled CCD camera (Photometrics, Tucson, AZ) connected to a computer work station running Metafluor imaging software. Excitation light was narrowly filtered (560 Ϯ 15 nm, Chroma Technology, Brattleboro, VT), and light emitted at 605 Ϯ 25 nm was measured. Images were formed using a ϫ40, 1.3 NA oil-immersion objective. An image of a drop of dye-free perfusate was used as a background. Non-uniform illumination (shading) in the imaging system was corrected by dividing each image by fluorescent image of a homogenous, uranium oxide slide, and the resultant image was scaled. Measurements were made every 20 s before, during, and after perfusion of rotenone. At the end of each experiment, we dissipated the proton gradient across the mitochondrial membrane with carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone to assess the proportion of ⌬⌿ m -independent TMRM fluorescence accumulation within mitochondria. Time-dependent changes in ⌬⌿ m were normalized both to baseline fluorescence intensity (100%) and to the fluorescence intensity remaining following carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (0%). To quantify TMRM fluorescence, mitochondria-rich regions were identified on TMRM images, and mean regional fluorescence was calculated for each cell in the image. Fluorescence intensity measurements were plotted on a region by region basis as a function of time.
Detection of Protein Carbonyls-Protein carbonyls were assayed with the Oxyblot protein oxidation detection kit (Intergen, Purchase, NY) at room temperature. Briefly, 15 g of protein was mixed with an equal volume of 12% SDS and 2 volumes of 1ϫ 2,4-dinitrophenylhydrazine solution. Control reactions used 1ϫ derivatization control solution instead of the 2,4-dinitrophenylhydrazine solution. The reaction proceeded for 15 min and was stopped by the addition of 1.5 volumes of neutralization solution. The samples were resolved by 12% SDS-PAGE and transferred to polyvinylidene difluoride membrane using semi-dry transfer. The membrane was washed twice for 5 min in PBS, blocked with PBS with 1% bovine serum albumin and 0.05% Tween 20 for 1 h, and incubated for 1 h in 1:150 rabbit anti-2,4-dinitrophenylhydrazone antibody (Intergen). The membrane was washed three times for 15 min in PBS and 0.05% Tween 20 and incubated in goat anti-rabbit IgG (1:300) for 1 h. After three washes in PBS and 0.05% Tween 20, the blot was detected using enhanced chemiluminescence (ECL, PerkinElmer Life Sciences).
Antioxidant Enzyme Assays-Superoxide dismutase activity was assayed with superoxide dismutase assay kit, WST (Dojindo Molecular Technologies, Gaithersburg, MD). 2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium is reduced by superoxide and produces a water-soluble formazan dye that can be detected with spectrophotometry. The inhibitory effect of superoxide dismutase on this reduction was measured to calculate superoxide dismutase activities. Catalase activity was measured with Amplex Red Catalase Assay Kit (Molecular Probes). After incubating the samples with 40 M H 2 O 2 for 30 min, the remaining H 2 O 2 was measured to determine the catalase activity. Amplex Red and horseradish peroxidase react with H 2 O 2 to produce resorufin, a fluorescent compound detectable with spectrophotometry. Glutathione peroxidase activity was measured with Bioxytech GPx-340 assay kit (OxisResearch, Portland, OR). tert-Butyl hydroperoxide was first reduced by glutathione peroxidase and recycled by glutathione reductase coupled with NADPH oxidation. The rate of decrease in NADPH is measured with spectrophotometry to estimate glutathione peroxidase activity.
Protein Levels-Protein assays were carried out using the Bio-Rad Protein Assay. Absorbance at A 595 nm was measured using a 96-well plate reader (25) .
Statistical Analysis-Data were analyzed using Sigma Stat software (SPSS Inc., Chicago, IL). Standard errors were determined for each group, and two-or three-way randomized ANOVA (depending on the experiments) followed by Tukey's post-hoc test was used to determine statistical differences between groups. A significance level of p Ͻ 0.05 was used.
RESULTS

Cellular Model of Dopaminergic Neuronal Degeneration-To
determine the effects of chronic, low-grade Complex I inhibition on cell degeneration in dopaminergic and non-dopaminergic cells, we induced cell cycle arrest and morphologic neuronal differentiation in immortalized midbrain MN9 neuronal cells using NaBu (20) . Prior to NaBu treatment, proliferating MN9 cells had small, roundish somata with occasional short neurites. After treatment with NaBu (1 mM) for several days, MN9 cells stopped dividing and adopted a mature neuronal morphology, characterized by long, well developed neurites (Fig. 1A) . Stable cell numbers were maintained for about 7-10 days after differentiation. Therefore, unless otherwise noted, rotenone studies were performed after 5-6 days of differentiation.
To characterize differentiated MN9D and MN9X cells, we stained cells for neuronal and non-neuronal markers. Both MN9D and MN9X cells stained strongly for neuronal markers NF and glutamic acid decarboxylase (Fig. 1A) . Neither cell type expressed immunoreactivity for GFAP, a non-neuronal marker (Fig. 1B ). These data demonstrate that differentiated MN9D and MN9X cells are both neuronal. Of these neuronal cells, MN9D cells exhibited tyrosine hydroxylase immunoreactivity and MN9X did not (Fig. 1, A and B) .
In MN9D cells, NaBu-induced morphological and immunohistochemical differentiation was accompanied by an enhanced dopaminergic phenotype. Specifically, the total cellular dopamine level in MN9D increased by about 8-fold, from 1.57 (Ϯ0.24) ϫ 10 Ϫ5 pmol/cell (S.E., n ϭ 3) to 12.7 (Ϯ0.9) ϫ 10 Ϫ5 pmol/cell (S.E., n ϭ 3). In contrast, NaBu-treated MN9X cells contained no dopamine. These data demonstrate that NaBu treatment of MN9D and MN9X cells produces differentiated, non-proliferating neuronal cells of dopaminergic and non-dopaminergic phenotype, respectively.
Differentiated MN9D Cells Provide an in Vitro Model of Selective Vulnerability of Dopaminergic Neurons to Rotenone
Toxicity-Selective rotenone toxicity to dopaminergic neurons has been noted in vivo following chronic, low dose paradigms (9), but not in acute, high dose paradigms (26) . We therefore compared the effects of micromolar (high dose) and nanomolar (low dose) concentrations of rotenone toxicity in MN9 cells. High dose rotenone (5-80 M for 60 h) induced a marked, dose-dependent death in all MN9 cells, without significant differences between dopaminergic and non-dopaminergic phenotypes ( Fig. 2A) . In contrast, low dose rotenone (5-80 nM for 7 days) produced dose-dependent toxicity against MN9 cells (p Ͻ 0.001 by two-way ANOVA) with greater toxicity seen in MN9D cells than in MN9X (p Ͻ 0.05; Fig. 2B ). Longer durations of rotenone treatment, up to 3 weeks, exaggerated the differential toxicity of MN9D versus MN9X (data not shown). To confirm that this differential susceptibility to low dose rotenone of dopaminergic MN9D cells was not the result of a nonspecific difference in vulnerability of the cells to a toxic stimulus, we induced apoptosis in both cell types, using staurosporine (5-500 nM) for 3 days, and compared survival as a function of dose. No significant differences in survival between MN9D and MN9X cells were detected (Fig. 2C) . Thus, administration of nanomolar concentrations of rotenone for 1 week recapitulates in vitro the phenomenon of differential susceptibility of dopaminergic neurons to chronic low-grade mitochondrial complex I inhibition.
Oxidative Stress Does Not Contribute to Rotenone Toxicity in Dopaminergic Cells-Because complex I inhibition increases mitochondrial oxidant production, one mechanism by which rotenone could cause differential toxicity in dopaminergic and non-dopaminergic cells is through differential, intrinsic susceptibility to oxidative stress. Accordingly, we assessed the susceptibility of MN9D and MN9X cells to 24 h exposure to the oxidants H 2 O 2 and tert-butyl hydroperoxide (tBOOH). Both H 2 O 2 and tBOOH killed MN9X and MN9D cells in a dose-dependent fashion (Fig. 3, A and B) . However, H 2 O 2 and tBOOH killed more non-dopaminergic MN9X cells than dopaminergic MN9D cells. This differential toxicity was observed at 80 M H 2 O 2 and 50 -100 M tBOOH (Fig. 3, A and B ; p Ͻ 0.001 for the interaction between tBOOH treatment and cell type by threeway ANOVA). In fact, tBOOH (100 M) resulted in 13.1 Ϯ 22.9% survival of MN9X cells, whereas 81.7 Ϯ 7.7% of MN9D cells survived. These data indicate that MN9D cells have decreased susceptibility to oxidant stress compared with MN9X.
To assess the role of oxidant stress in killing MN9D and MN9X cells during low dose rotenone treatment, we first asked whether antioxidant treatment differentially improves survival of MN9D and MN9X cells during low dose rotenone. MN9D and MN9X cells were treated with rotenone (5-80 nM) for 1 week in the presence and absence of Euk-134 (5 M), a superoxide dismutase and catalase mimetic (27) . Euk-134 did not protect MN9D cells against rotenone toxicity (Fig. 4A) . In contrast, Euk-134 significantly improved survival of non-dopaminergic MN9X cells after 1 week in the presence of rotenone to the extent that it completely prevented low dose rotenoneinduced death (p Ͻ 0.05, Fig. 4B ). To exclude the possibility that the lack of antioxidant-induced protection in MN9D cells was because of the greater degree of rotenone toxicity in MN9D compared with MN9X in this dose range, we compared the effects of Euk-134 treatment on MN9 toxicity following 40 nM rotenone treatment in MN9X cells with 5 nM rotenone treatment in MN9D cells, doses that induce similar degrees of death in each cell type. In this comparison, we observed no protective effect of Euk-134 in MN9D cells, confirming that MN9X survival following low dose rotenone is differentially improved by antioxidants. Combined, these data indicate that rotenone induces toxic oxidative stress only in MN9X cells, and that this non-dopaminergic cell type exhibits increased vulnerability to oxidative stress compared with MN9D cells.
Having found less susceptibility of MN9D cells to exogenous oxidant stress and rotenone-induced endogenous oxidative stress compared with MN9X cells, we next assessed whether rotenone treatment amplifies vulnerability to exogenous oxidants. MN9D and MN9X cells were treated with rotenone (40 nM) for only 3 days, a treatment that does not significantly increase cell death. For the last 24 h of this treatment, we added tBOOH in a range of doses. Rotenone treatment markedly worsened survival of MN9X cells following tBOOH (90 Ϯ 5% tBOOH (25 M) alone versus 67 Ϯ 3% tBOOH (25 M) plus rotenone; 45 Ϯ 10% tBOOH (50 M) alone versus 22 Ϯ 20% tBOOH (50 M) plus rotenone; p Ͻ 0.001 by three-way ANOVA) (Fig. 3C) . In contrast, rotenone had no significant effect on susceptibility of MN9D cells to tBOOH. Thus, non-dopaminergic MN9X cells exhibit increased vulnerability to oxidants compared with dopaminergic MN9D cells, and this differential susceptibility is widened in response to added chronic complex I inhibition. Accordingly, rotenone may generate more oxidant stress in MN9X cells, compared with MN9D cells.
To directly assess whether rotenone generates less oxidant stress in MN9D cells than in MN9X cells, we treated MN9D and MN9X cells with rotenone (5 nM), a regimen producing toxicity in MN9D, but not MN9X cells, and measured changes in protein carbonyl levels at multiple times during the 3-week treatment period. Rotenone produced increased levels of protein carbonyls in both cell types. However, at each measurement time, non-dopaminergic MN9X cells exhibited a greater increase in protein carbonyl level compared with dopaminergic MN9D cells (Fig. 5A) . These increased levels in MN9X cells demonstrate that MN9X cells undergo greater rotenone-induced protein oxidation than MN9D cells. To further explore the differential response of MN9D and MN9X cells to oxidants, cells were treated with H 2 O 2 (0 -40 M) for 72 h, and protein carbonyls were measured. Consistent with increased susceptibility of MN9X cellular proteins to oxidative stress, H 2 O 2 induced a marked greater increase of protein carbonyls in MN9X compared with MN9D (Fig. 5B) .
To investigate the intrinsic antioxidant capacities of these cells, we measured activities of the major antioxidant enzymes, superoxide dismutase, catalase, and glutathione peroxidase. We observed no significant activity differences in any of these enzymes between cell types (Table I) . We have previously found tetrahydrobiopterin (BH 4 ), a cofactor for tyrosine hydroxylase, to have antioxidant activity, scavenge superoxide, and protect cells from oxidative stress (28, 29) . As expected from having a dopaminergic phenotype, MN9D cells had much higher BH 4 levels compared with MN9X (Table I) .
Collectively, these data demonstrate that MN9D cells are less susceptible to oxidative injury and death than non-dopaminergic MN9X cells, and that rotenone-induced death occurs via oxidative mechanisms in MN9X cells, but oxidative stress is relatively well tolerated in MN9D cells and therefore, oxidative mechanism is not likely to be the main pathway leading to cell death in MN9D cells.
Rotenone Decreases Mitochondrial Membrane Potential More in MN9D Cells-Having found that oxidative stress is better compensated in MN9D cells than in MN9X cells, and that oxidative stress is not likely to be the main mechanism of selectively increased death of dopaminergic MN9D cells following low dose rotenone, we assessed whether low dose rotenone differentially disrupts mitochondrial function in dopaminergic and non-dopaminergic cells. First, we compared the effect of rotenone on the rates of oxygen consumption in differentiated MN9D and MN9X cells. Rotenone significantly decreased oxygen consumption in both cell types in a dose-dependent manner (p Ͻ 0.001 by two-way ANOVA). However, there was no significant interaction between cell type and the magnitude of the rotenone-induced decrease in respiration (p ϭ 0.74) (Fig. 6A) . Thus, there were no intrinsic differences in rotenone sensitivity of electron transport activity between the two cell lines.
We then assessed the ability of MN9D and MN9X cells to maintain stable ⌬⌿ m in the face of mitochondrial complex I inhibition using TMRM microfluorimetry of single cells. At baseline, TMRM fluorescence was stable over time in MN9D and MN9X cells, and we observed no differences in fluorescence intensity using identical camera settings and loading conditions. Application of rotenone at concentrations less than 100 nM failed to acutely dissipate ⌬⌿ m . However, rotenone (100 nM) dissipated ⌬⌿ m in both cell types within 1-2 min (Fig.  6B) . At this concentration, rotenone decreased TMRM fluorescence faster and to a significantly greater extent in MN9D cells compared with MN9X cells (29.9 Ϯ 6.04 MN9D versus 20.57 Ϯ 5.48% MN9X; n ϭ 21, p Ͻ 0.0005 by one-way ANOVA, Fig. 6B) .
Dopaminergic Cells Are More Susceptible to Energy Depletion-Because rotenone disrupted ⌬⌿ m more in dopaminergic cells, we hypothesized that low dose rotenone may induce greater energy depletion in dopaminergic cells. Accordingly, we assessed whether dopaminergic MN9D cells are more susceptible to energy depletion, by measuring changes in low dose rotenone-induced survival of MN9D and MN9X cells following modulation of mitochondrial ATP synthesis and glycolysis.
We first abolished mitochondrial ATP synthesis by inhibiting the mitochondrial F 1 -F 0 ATPase with oligomycin. Oligomycin (2-50 nM) treatment for 1 week was more toxic to MN9D cells than MN9X cells at all doses employed, indicating that the MN9D cells were more dependent on mitochondrial ATP synthesis (Fig. 7A) .
Having found that MN9D cells depend more on mitochondrial ATP synthesis than MN9X cells, we assessed whether these cells had a similarly increased dependence on glycolysis. We inhibited glycolysis by culturing cells in media supplemented with 2-deoxyglucose (5 mM), a competitive inhibitor of glucose transport and phosphorylation. Following 1 week of glycolysis inhibition, MN9D cells exhibited significantly increased mortality from baseline, whereas MN9X cells did not (Fig. 7B) . We next assessed whether concomitant inhibition of glycolysis differentially affected toxicity because of low dose rotenone. Addition of rotenone (2.5-10 nM) for 1 week to 2-deoxyglucose-exposed cells significantly increased MN9D mortality at all rotenone doses. In contrast, glycolysis inhibition increased susceptibility of MN9X cells to rotenone only at doses greater than 2.5 nM.
We next examined whether alteration of glucose availability would similarly increase rotenone toxicity of only dopaminergic cells. MN9D and MN9X cells, cultured in various concentrations of glucose (0 to 25 mM), were treated with rotenone (10 nM) for 7 days (Fig. 7C) . Glucose concentrations below 2.5 mM significantly increased the susceptibility of MN9D cells to rotenone toxicity (p Ͻ 0.001 by two-way ANOVA). However, rotenone toxicity in MN9X cells was not affected by any glucose concentration employed, including complete absence of glucose.
Having found that dopaminergic MN9D cells were more susceptible to inhibition of multiple metabolic pathways, we tested whether rotenone kills MN9D cells through metabolic inhibition. To test this hypothesis, we supplemented cultures with D-␤-hydroxybutyrate, a ketone body that provides an alternative energy source to glucose during mitochondrial inhibition, prior to and during exposure to low dose rotenone. a SOD, superoxide dismutase; GPx, glutathione peroxidase; ND, not detectable (our GPx assay sensitivity limit is 0.6 unit/mg); and BH 4 , tetrahydrobiopterin.
b Mean Ϯ S.E., p Ͻ 0.001 by t test, n ϭ 7 for BH 4 ; p Ͼ 0.05 for SOD; n ϭ 3-4 for catalase and GPx.
rotenone plus D-␤-hydroxybutyrate; p Ͻ 0.05; Fig. 8 ). In contrast, D-␤-hydroxybutyrate did not alter the survival of MN9X cells following rotenone. These data suggest that our dopaminergic, but not non-dopaminergic, cells succumb to rotenone as a result of greater susceptibility to rotenone-induced energy deprivation. 
Distinct Mechanisms of Toxicity by Complex I Inhibition 51789
Because our data indicated that low dose rotenone treatment deprives dopaminergic MN9D cells of energy when these cells are at an inherent metabolic disadvantage compared with nondopaminergic MN9X cells, we directly assessed whether rotenone differentially alters ATP levels in MN9D and MN9X cells. Intracellular ATP content was compared in MN9D and MN9X cells treated at baseline and after rotenone (5 nM) treatment for 72 h (Fig. 9) . At baseline, mean ATP levels in MN9D cells were almost double that of MN9X cells (p Ͻ 0.001). Low dose rotenone had no effect on ATP levels in MN9X cells. In contrast, rotenone significantly decreased ATP levels in MN9D cells by almost 50% (p Ͻ 0.05).
Because dopamine has been implicated in the generation of oxidative stress, and can also affect mitochondrial function (30), we asked whether the presence of dopamine in MN9D cells contributes to their increased susceptibility to rotenone. MN9D cells were treated for 7 days with ␣-methyldopa (50 M) to inhibit tyrosine hydroxylase and block dopamine synthesis, along with reserpine (10 nM) to deplete the intracellular storage of dopamine. This treatment decreased dopamine levels to 4.8 Ϯ 2.6% of untreated MN9D cells. However, following rotenone treatment, survival of dopamine-depleted MN9D cells was no higher than the survival of control MN9D cells (58.4 Ϯ 3.0 versus 61.1 Ϯ 2.2%, n ϭ 5, p Ͼ 0.05).
DISCUSSION
Long-term exposure to low concentrations of rotenone produces selective damage to dopaminergic neurons in vivo (9) , whereas high doses produce indiscriminate and acute toxicity (13, 26) . The goal of this study was to explore the cellular mechanisms of cell death in related, differentiated dopaminergic and non-dopaminergic cells subjected to chronic mitochondrial inhibition using a novel in vitro model of chronic lowgrade complex I inhibition. Because these cells could be kept in culture in a non-proliferating state, we were able to focus on the issue of survival without the compounding effects of toxins and treatments on proliferation. In addition, non-proliferating cells avoid the potential problems associated with selection of a resistant population during long-term exposure to a stressinducing stimulus. Differentiated dopaminergic MN9D and non-dopaminergic MN9X cells provide an ideal culture model to study the effects of chronic toxicity in dopaminergic cells with the convenience of cell lines.
Using these two cell types, we observed selective vulnerability of dopaminergic cells to low dose chronic rotenone exposure compared with non-dopaminergic cells, with increasing selectivity observed over time. Importantly, our observation that dopamine depletion failed to increase survival of dopaminergic cells following rotenone indicates that endogenous levels of dopamine itself does not contribute to this selective vulnerability. Furthermore, unlike 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, rotenone does not rely on specific dopamine uptake mechanisms or receptors to accumulate selectively in high concentrations in dopaminergic neurons. Therefore, selective vulnerability to rotenone in MN9D cells indicates the presence of intrinsic vulnerability factors unrelated to the dopamine system. Rotenone can stimulate reactive oxygen species generation from mitochondrial complex I (31, 32) , as long as reduced NADH is available (33) , and intrinsic vulnerability to oxidative stress has been suggested to underlie the selective death of dopaminergic cells. However, using cell survival and measurements of protein carbonyls, we found dopaminergic cells to be clearly more resistant to exogenous oxidants. Furthermore, we found that low dose rotenone in dopaminergic cells fails to increase the minimal toxicity from exogenous oxidants. We conclude, therefore, that, in this paradigm, dopaminergic cells do not succumb to rotenone via oxidative stress. Consistent with our findings, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice can be attenuated by D-␤-hydroxybutyrate, which increases ATP levels, but does not have antioxidant effects (34) .
We have previously shown that primary midbrain dopaminergic neurons produce less reactive oxygen species than nondopaminergic midbrain neurons (13) , and are more resistant to the oxidant stresses of glutathione depletion or H 2 O 2 treatment (29) . Although it is difficult to separate differences in oxidant production and antioxidant capacities in whole cells, the higher glutathione levels in dopaminergic midbrain neurons compared with non-dopaminergic cells we have previously reported, as well as the presence of tetrahydrobiopterin, a scavenger of superoxide, only in dopaminergic neurons (28, 29) likely are significant contributors to this increased antioxidant capacity in dopaminergic neurons. In the present study, we found no differences in activity levels of major antioxidant enzymes between MN9D and MN9X cells. However, we did observe a greater than 2-fold increase in tetrahydrobiopterin levels in MN9D cells compared with MN9X cells. Collectively, our data challenge the notion that oxidative stress is the only critical component of dopaminergic cell degeneration, and indicate that other mechanisms may play an important role in selective vulnerability of dopaminergic neurons depending on the intrinsic antioxidant capacities of the cells.
In this study, we obtained multiple lines of evidence indicating that non-dopaminergic cells are more susceptible to oxidative stress than dopaminergic cells: 1) compared with dopaminergic cells, non-dopaminergic cells were more susceptible to exogenous oxidants; 2) low dose rotenone increased the sensitivity to exogenous oxidants only in non-dopaminergic cells; 3) antioxidants protected only non-dopaminergic cells from rotenone toxicity; 4) although H 2 O 2 and rotenone markedly increased protein carbonyls in both cell types, protein carbonyls were increased to a much greater extent in non-dopaminergic cells. These results are consistent with our previous studies in primary midbrain neuronal cultures, in which we observed more baseline reactive oxygen species production and less reactive oxygen species scavenging in non-dopaminergic cells compared with dopaminergic cells, and a decreased resistance to oxidative stress (28) . In addition, we have previously shown that rotenone augments superoxide generation in non-dopaminergic but not dopaminergic neurons (13) . Together, these lines of evidence demonstrate that intrinsic, cell type-specific, antioxidant systems determine whether rotenone-induced oxidative stress becomes sufficient to trigger cell death.
Our study reveals that intrinsic differences exist between the bioenergetic requirements of dopaminergic and non-dopaminergic cells. First, baseline ATP levels were higher in MN9D cells than in MN9X cells, suggesting an overall higher energy demand by dopaminergic cells. Consistent with a greater phenotypic sensitivity to low concentrations of rotenone, mitochondrial membrane potential decreased to a greater extent in MN9D cells challenged with rotenone than in MN9X cells. Rotenone also decreased ATP levels to a greater extent in MN9D cells than MN9X cells. A greater sensitivity to metabolic inhibition by low concentrations of rotenone, combined with a greater dependence on mitochondrial ATP production, could therefore explain why rotenone preferentially kills dopaminergic neurons. Finally, MN9D cells were more susceptible to disruption of the cellular energy supply at multiple levels. These findings indicate that the requirement for and utilization of energy is greater in dopaminergic than in non-dopaminergic cells. Thus, differences in bioenergetic demand seem to be a much more important contributor to rotenone toxicity than is oxidant stress in these dopaminergic cells.
The notion that the cellular bioenergetic state is critical for the survival of dopaminergic neurons is further supported by our observation that supplementation of MN9D cells with the ketone body, D-␤-hydroxybutyrate, markedly reduced toxicity following low dose rotenone, presumably by enhancing cellular energy state. ATP depletion has also been observed as a primary consequence of MPP ϩ toxicity in hepatocytes (35), brain mitochondria (36) , and mouse striatum (37, 38) , and providing metabolites of glycolysis attenuates it (39) . Similarly, supplementation with D-␤-hydroxybutyrate, as well as glucose, protects neurons from MPP ϩ toxicity in vitro and in vivo (34, 40, 41) . Accordingly, the importance of bioenergetics in the pathogenesis of PD warrants further investigation (42) .
In conclusion, our use of differentiated MN9D and MN9X cells has enabled us to study the cellular mechanisms underlying the selective vulnerability of dopaminergic cells to chronic, low dose rotenone treatment, a paradigm that is relevant to the pathogenesis of PD. Use of this model has revealed profound differences between dopaminergic and non-dopaminergic cells in their responses to chronic inhibition of mitochondrial complex I. Specifically, we have found that dopaminergic MN9D cells succumb to rotenone as a consequence of metabolic inhibition. Importantly, rotenone-induced death in these cells does not occur by oxidant stress-related mechanisms nor in a dopamine-dependent fashion. In contrast, we have found that non-dopaminergic MN9X cells do succumb to low dose rotenone as a consequence of increased oxidative stress. Collectively these studies illustrate the importance of intrinsic properties of cell types in understanding the mechanisms of cell death in PD models involving Complex I inhibition. Further studies examining the intrinsic properties underlying the increased susceptibility to energy deprivation, and the enhanced sensitivity to environmental toxins in dopaminergic cells compared with non-dopaminergic cells may provide us with a better understanding of the pathogenesis of PD and lead to rational therapeutic strategies.
